GlassScriptPhysician profile
Shiow J Cheng
NPI 1114020526
$4,159.84
in general payments reported to CMS, 2019-2025
42 companies · $1,261 in 2025
The $1,261 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $335 · 2020: $28.74 · 2021: $14.39 · 2022: $203 · 2023: $1,097 · 2024: $1,220 · 2025: $1,261.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,578.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,578.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $802.69 | 2019-2025 | Xifaxan, Trulance |
| Novo Nordisk INC | $731.31 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $326.33 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $250.91 | 2023-2025 | Rexulti, Abilify Asimtufii |
| Exact Sciences Corporation | $195.15 | 2023-2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $183.49 | 2019-2025 | Zepbound, Mounjaro, Kisunla |
| Janssen Pharmaceuticals, INC | $159.94 | 2019-2024 | Spravato |
| Kowa Pharmaceuticals America, INC. | $122.02 | 2022-2025 | Zoryve, Seglentis, Livalo |
| Abbott Laboratories | $110.32 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Almatica Pharma LLC | $87.60 | 2023-2024 | Loreev Xr, Gralise, Sertraline Hcl |
| Astrazeneca Pharmaceuticals LP | $82.42 | 2019-2025 | Breztri, Farxiga |
| Merck Sharp & Dohme LLC | $82.37 | 2019-2025 | Verquvo, Lagevrio |
| Pfizer INC. | $81.08 | 2019-2025 | |
| Glaxosmithkline, LLC. | $77.80 | 2019-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Eisai INC. | $74.62 | 2023-2024 |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $73.32 | 2025 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $61.84 | 2023-2024 | Tradjenta, Jardiance, Synjardy |
| Idorsia Pharmaceuticals US INC | $59.09 | 2023-2024 | Quviviq |
| Astellas Pharma US INC | $53.78 | 2019-2024 | Veozah |
| Sanofi-Aventis U.S. LLC | $47.48 | 2022-2025 | |
| Lundbeck LLC | $43.06 | 2022-2024 | Rexulti |
| Alkermes, INC. | $37.68 | 2023 | Aristada, Lybalvi |
| Novartis Pharmaceuticals Corporation | $36.75 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $36.04 | 2025 | Caplyta |
| Abbvie INC. | $32.96 | 2022-2025 | |
| Nevro Corp. | $31.50 | 2023 | Senza |
| Horizon Therapeutics Plc | $30.00 | 2019-2020 | |
| Amgen INC. | $28.53 | 2019-2023 | Prolia, Evenity |
| Medtronic, INC. | $24.26 | 2024 | Intellis Adaptivestim |
| Daiichi Sankyo INC. | $20.04 | 2025 | Injectafer |
| Insmed, INC. | $17.67 | 2024 | Arikayce |
| Depuy Synthes Sales INC. | $17.40 | 2023 | Orthovisc, Monovisc |
| Ibsa Pharma INC. | $17.39 | 2024 | Licart, Tirosint |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $16.43 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $14.87 | 2024 | Camzyos |
| Jazz Pharmaceuticals INC. | $14.19 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.07 | 2019 | |
| Vanda Pharmaceuticals INC. | $13.74 | 2020 | |
| Hikma Pharmaceuticals USA | $13.28 | 2019 | |
| Sumitomo Pharma America, INC. | $12.54 | 2023 | Gemtesa |
| Allergan, INC. | $12.00 | 2019 | |
| Xeris Pharmaceuticals, INC. | $11.88 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shiow Cheng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.